INmune Bio announces Cell Reports publication showing XPro1595 promotes remyelination

Inmune Bio, Inc.

Publication in Cell Reports demonstrates XPro1595 converts microglia from demyelinating to remyelinating cell.
Study led by Hellenic Pasteur Institute; identifies solTNF as critical checkpoint for microglia polarization.
Demyelination is core mechanism in neurodegeneration; XPro1595 targets solTNF to restore glia function.
INmune expects top-line Phase II cognitive results in early Alzheimer's patients in first half of 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.